Retrospective comparison between COBE SPECTRA and SPECTRA OPTIA apheresis systems for hematopoietic progenitor cells collection for autologous and allogeneic transplantation in a single center

Abstract

Introduction COBE SPECTRA [COBE] (Terumo, BCT Lakewood CO) apheresis system has been the most used device for hematopoietic progenitor cells (HPC) collection. Recently, it has been replaced by the SPECTRA OPTIA [OPTIA] (Terumo, BCT Lakewood CO) apheresis system. The aim of our study is to compare both methods for HPC collection. Material and methods We retrospectively compared 302 HPC collection apheresis procedures (115 allogeneic donors and 187 autologous). The study cohort was divided according to the apheresis system used to analyze the differences between COBE and OPTIA, specifically efficacy of apheresis procedure and product characteristics. Results OPTIA collections result in a higher CD34+ collection efficiency in both groups (autologous 45.3% vs 41%, P < .006; allogeneic 54.9% vs 45%, P < .0001). The total of CD34+ cells ×106 /kg recipient collected in the product were comparable in both groups (autologous 2.9 in OPTIA group vs 2.8 in COBE group, P = .344; allogeneic 6.2 in OPTIA group vs 5.8 in COBE group, P = .186). The percentage of platelet loss in autologous donors was significantly lower (35.7% vs 40.8%, P < .01). Regarding quality of the product, we observed a significantly lower hematocrit in products collected with OPTIA in both groups (1.8% vs 4%, P < .0001) as well as significantly lower amount of leukocytes (median 153.4 vs 237.2 × 109/L in autologous, P < .0001; 239.5 vs 340.2 × 109/L in allogeneic P < .0001). Conclusion Both apheresis systems are comparable in collection of hematopoietic progenitor cells, with significantly higher collection efficiency with the OPTIA system. Collection products obtained with OPTIA contain significantly lower hematocrit and leukocytes.

Stem‐cell mobilization of healthy sibling donors with pegfilgrastim—A prospective open‐label phase II trial (EudraCT no: 2005‐004971‐39)

“…The collections for the trial were conducted on the Cobe Spectra device. Having in mind that the collection efficacy of Cobe Spectra and Spectra Optia regarding the collection of progenitor stem cells are comparable, 24,25 we can conclude that the data from our trial can be used in current stem‐cell collection settings. Furthermore, we are the first to report about the pharmacokinetics of pegfilgrastim in healthy stem‐cell donors.…”

Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor‐mobilized patients with sickle cell disease

“…To examine how the collection depth affects CE and cellular contents of the HSPC product, we divided the collections into two groups, medium CP and low CP (Table 1 and Figure S1). Medium and low CPs improved CE to the levels comparable to standard HSPC collection from individuals without SCD 11,12 . In particular, low CP led to significantly more efficient collection than did medium CP [CE1: 82.23% (IQR: 44.43%–96.54%) vs. 35.79% (IQR: 24.78%–39.61%), p = 0.016; CE2: 73.10% (IQR: 44.43%–81.02%) vs. 25.24% (IQR: 19.35%–31.12%), p < 0.001].…”

“…Medium and low CP increased RBC contamination of the product. 11,12 Low CP was associated with a significantly higher haematocrit of the product than medium CP [6.4% (IQR: 5.5%-7.7%) vs. 4.7% (IQR: 4.2%-6.1%), p = 0.009]. Nevertheless, participants using low CP experienced no more Hct reduction in peripheral blood…”

“…Medium and low CPs improved CE to the levels comparable to standard HSPC collection from individuals without SCD. 11,12 In particular, low CP led to significantly more efficient collection than did medium CP [CE1: 82.23% (IQR: 44.43%-96.54%) vs. 35.79% (IQR: 24.78%-39.61%), p = 0.016; CE2: 73.10% (IQR: 44.43%-81.02%) vs. 25.24% (IQR: 19.35%-31.12%), p < 0.001]. The HSPC yield of the low-CP group was also higher than that of the medium-CP group, although not statistically significant [5.51 (IQR: 3.45-9.93) × 10 6 CD34 + cells/kg vs. 2.74 (IQR: 1.68-6.75) × 10 6 CD34 + cells/kg, p = 0.41).…”

Leukapheresis and Hyperleukocytosis, Past and Future

“…So far, the most widely used blood cell separators in hospitals are the SPECTRA OPTIA, Fresenius COM.TEC, Fenwal Amicus and Trima Accel. 19 The principle of these machines depends on the gradient density difference between different cells. Platelets and erythrocytes often contaminate the collected leukocytes due to low density of blood components (1.6%–2.2%), and ultimately results in the erythrocyte and platelet loss.…”